Stocks Bristol-Myers Squibb Co

More

  • Nov 17- The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The United States and New Zealand are the only two countries that allow direct-to-consumer advertising...

  • *Q3 profit $1.23/ shr vs. est. Nov 5- Celgene Corp posted its smallest revenue growth in five quarters due to slower sales of its two key cancer drugs. Growing sales of expensive new cancer drugs and other treatments helped top U.S. drugmakers such as Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co post stronger-than-expected quarterly profits last month.

  • LONDON, Nov 5- AstraZeneca lifted its full-year forecast for revenue and earnings on Thursday as Chief Executive Pascal Soriot said the group was showing resilience, despite eroding sales of some of its top-selling medicines. "Looking ahead, however, the continued performance of our growth platforms and upcoming launches will combine with our increasing...

  • Nov 2- Bristol-Myers Squibb Co said on Monday it bought privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion, to gain access to a heart failure treatment. At least 5.1 million Americans suffer from heart failure, for which there is no cure, according to the Centers for Disease Control and Prevention.

  • Nov 2- Bristol-Myers Squibb Co said it would buy privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion, to gain access to a heart failure treatment.

  • NEW YORK, Oct 27- Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits. The results, announced on Tuesday, demonstrate that the "patent cliff" that had been hurting earnings as huge-selling drugs like Pfizer's...

  • Early movers: DD, F, MRK, PFE, CMCSA, BABA & more Tuesday, 27 Oct 2015 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Lightning Round: It's overdone on the down side Monday, 26 Oct 2015 | 7:04 PM ET
    Mad Money Lightning Round

    Jim Cramer quickly gives his take to caller favorite stocks at lightning speed, including this play on commodities.

  • Markets get taste of Apple earnings ahead of Fed Monday, 26 Oct 2015 | 6:57 PM ET
    Trader on the floor of the New York Stock Exchange.

    Earnings news, especially from Apple, could stir up a market that's waiting for the Fed.

  • US Treasurys higher ahead of Fed, key earnings Monday, 26 Oct 2015 | 3:15 PM ET
    A trader signals an offer in a Treasury note options pit at the CME Group in Chicago.

    U.S. sovereign bonds traded higher on Monday ahead of the Federal Reserve's two-day policy meeting this week and a raft of major corporate earnings.

  • The "Halftime Report" traders give their top trades of the show.

  • Wall Street jittery ahead of bumper earnings week Monday, 26 Oct 2015 | 8:57 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a flat to mildly lower open as traders prepare for the Fed's two-day meeting this week and a slew of earnings.

  • Cramer Remix: These results were legendary Friday, 23 Oct 2015 | 7:02 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer takes the time to reveal the stocks that are running away from the competition.

  • Cramer's game plan: Apple could get a bruising Friday, 23 Oct 2015 | 6:14 PM ET
    Apple's iPhone 6 are displayed as people browse through products at a store in Atlantic City, New Jersey.

    Jim Cramer cannot believe what a stellar week of earnings this was. Now that the bar is set so high, he warned that Apple could get hurt next week.

  • Fed could be a snooze, but these reports will be big Friday, 23 Oct 2015 | 4:52 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.

  • Net profit rose to $799.7 million, or 75 cents per share, in the third quarter ended Sept. 30, from $500.6 million, or 47 cents per share, a year earlier. Excluding special items, the company earned 89 cents per share, handily beating the average analyst expectation of 76 cents per share. The Indianapolis- based drugmaker said it now expected full-year profit of $3.40-...

  • Oct 16- The most influential source for U.S. oncology treatment guidelines on Friday unveiled ratings aimed at helping doctors and patients assess the costs versus benefits of current therapies for two types of blood cancer. Craig Hofmeister, a hematologist with the Ohio State University Comprehensive Cancer Center and a member of the NCCN myeloma...

  • In examples released on Friday, NCCN rated primary treatments for CML: Bristol-Myers Squibb's Sprycel, and Novartis AG's Gleevec and Tasigna. For newly diagnosed myeloma patients eligible for a stem cell transplant, NCCN lists six "preferred" regimens, four of which contain Takeda Pharmaceutical Co's Velcade and various chemotherapies, one that includes...

  • The FDA in 2010 approved Pradaxa to prevent stroke in patients with a common heart rhythm irregularity called atrial fibrillation. Praxbind, an intravenous injection, is the first reversal agent approved specifically for Pradaxa and works by binding to the drug compound to neutralize it, the FDA said. Portola Pharmaceuticals Inc plans before the end of 2015...

  • Oct 15- Bristol-Myers Squibb Co said on Thursday it agreed to exclusively license and collaborate with Five Prime Therapeutics Inc to develop and commercialize Five Prime's antibody program in the treatment of cancer. Five Prime will receive $350 million upfront and potential development and regulatory milestone payments, totaling $1.74 billion, for the...